This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Brunswick (NYSE:BC), Cellectis (NASDAQ:CLLS)

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Brunswick (NYSE:BC), Cellectis (NASDAQ:CLLS)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page .

Clear Street analyst Bill Maughan initiated coverage on Cellectis SA (NASDAQ: CLLS ) with a Buy rating and announced a price target of $9. Cellectis shares closed at $4.69 on Monday. See how other analysts view this stock . Raymond James analyst Rick Patel initiated coverage on Levi Strauss & Co. (NYSE: LEVI ) with an Outperform rating and announced a price target of $26. Levi Strauss shares closed at $21.23 on Monday. See how other analysts view this stock . Oppenheimer analyst Leland Gershell initiated coverage on Spruce Biosciences, Inc. (NASDAQ: SPRB ) with an Outperform rating and announced a price target of $283. Spruce Biosciences shares closed at $82.82 on Monday. See how other analysts view this stock . Jones Trading analyst Catherine Novack initiated coverage on Septerna, Inc. (NASDAQ: SEPN ) with a Buy rating and announced a price target of $43. Septerna shares closed at $29.47 on Monday. See how other analysts view this stock . Loop Capital initiated coverage on Brunswick Corporation (NYSE: BC ) with a Hold rating and announced a price target of $74. Brunswick shares closed at $76.64 on Monday. See how other analysts view this stock.

Considering buying LEVI stock? Here’s what analysts think:

Read This Next:

5 Stock Picks Last Week From Wall Street’s Most Accurate Analysts

Photo via Shutterstock

BC Brunswick Corp $76.39 -0.27% Overview CLLS Cellectis SA $4.90 4.48% LEVI Levi Strauss & Co $21.45 1.06% SEPN Septerna Inc $28.95 -1.78% SPRB Spruce Biosciences Inc $84.35 1.85% Market News and Data brought to you by Benzinga APIs

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Add Comment | 1
Posted In: News Initiation Markets Analyst Ratings Trading Ideas Top Initiations